Epigenetic biomarkers in the diagnosis of ovarian cancer

Jonathan G. Bijron, Guus M. Bol, Rene H M Verheijen, Paul J. Van Diest

Research output: Contribution to journalArticle

Abstract

Current diagnostic methods for ovarian cancer have limited performance. Recent advances within the field of epigenetics have shifted the clinical implementation of epigenetic biomarkers as a diagnostic approach from a dream for the future to a present-day consideration. Patients could potentially benefit greatly from this novel diagnostic approach. Areas covered: Epigenetic mechanisms in cancer are discussed, with a focus on potential diagnostic epigenetic biomarkers in ovarian cancer in tissue and body fluids. A literature search was undertaken (on 22-09-2011) for these subjects using the search syntax ((((((((((((((("ovarian") OR "ovary") OR "ovarian cancer") OR "ovarian cancers") OR "cancer of the ovary") OR "tumour of the ovary") OR "ovarian tumor") OR "ovarian tumors") OR "ovarian tumour") OR "ovarian tumours") OR "ovarian neoplasm") OR "ovarian neoplasms" OR "ovarian carcinoma") OR "ovarian carcinomas") OR "carcinoma of the ovary")) AND ((((((((("epigenetics") OR "epigenetic") OR "epigenome") OR "methylation") OR "hypermethylation") OR "chromatin modification") OR "histone") OR "histones") OR "acetylation") Expert opinion: To date no single epigenetic biomarker is able to accurately detect early ovarian cancer in either tissue or body fluids. A panel of epigenetic biomarkers based on aberrant DNA methylation in body fluids, especially blood, has the best chance of being implemented in clinical practice, as it is semi-invasive. However, progression toward clinical use is hampered by the lack of detection techniques combining high throughput and accuracy with low cost, by difficulties in establishing reliable reference values and by the heterogeneous nature of ovarian cancer. Until addressed, implementation as a diagnostic measure complimenting current techniques in select cases seems a far way to go, and implementation as a primary screening tool is yet even farther away.

Original languageEnglish (US)
Pages (from-to)421-438
Number of pages18
JournalExpert Opinion on Medical Diagnostics
Volume6
Issue number5
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

Biomarkers
Epigenomics
Ovarian Neoplasms
Tumors
Body fluids
Histones
Body Fluids
Ovary
Neoplasms
Tissue
Acetylation
Methylation
Carcinoma
Chromatin
Histone Code
Screening
Blood
Throughput
Expert Testimony
DNA Methylation

Keywords

  • biomarkers
  • borderline tumor
  • chromatin modification
  • diagnosis
  • epigenetics
  • methylation
  • ovarian cancer

ASJC Scopus subject areas

  • Biomedical Engineering
  • Medicine(all)
  • Biochemistry, medical
  • Molecular Medicine

Cite this

Bijron, J. G., Bol, G. M., Verheijen, R. H. M., & Van Diest, P. J. (2012). Epigenetic biomarkers in the diagnosis of ovarian cancer. Expert Opinion on Medical Diagnostics, 6(5), 421-438. https://doi.org/10.1517/17530059.2012.702105

Epigenetic biomarkers in the diagnosis of ovarian cancer. / Bijron, Jonathan G.; Bol, Guus M.; Verheijen, Rene H M; Van Diest, Paul J.

In: Expert Opinion on Medical Diagnostics, Vol. 6, No. 5, 09.2012, p. 421-438.

Research output: Contribution to journalArticle

Bijron, JG, Bol, GM, Verheijen, RHM & Van Diest, PJ 2012, 'Epigenetic biomarkers in the diagnosis of ovarian cancer', Expert Opinion on Medical Diagnostics, vol. 6, no. 5, pp. 421-438. https://doi.org/10.1517/17530059.2012.702105
Bijron, Jonathan G. ; Bol, Guus M. ; Verheijen, Rene H M ; Van Diest, Paul J. / Epigenetic biomarkers in the diagnosis of ovarian cancer. In: Expert Opinion on Medical Diagnostics. 2012 ; Vol. 6, No. 5. pp. 421-438.
@article{b25055ab2bb042f39eaca5de7cbe7a17,
title = "Epigenetic biomarkers in the diagnosis of ovarian cancer",
abstract = "Current diagnostic methods for ovarian cancer have limited performance. Recent advances within the field of epigenetics have shifted the clinical implementation of epigenetic biomarkers as a diagnostic approach from a dream for the future to a present-day consideration. Patients could potentially benefit greatly from this novel diagnostic approach. Areas covered: Epigenetic mechanisms in cancer are discussed, with a focus on potential diagnostic epigenetic biomarkers in ovarian cancer in tissue and body fluids. A literature search was undertaken (on 22-09-2011) for these subjects using the search syntax ((((((((((((((({"}ovarian{"}) OR {"}ovary{"}) OR {"}ovarian cancer{"}) OR {"}ovarian cancers{"}) OR {"}cancer of the ovary{"}) OR {"}tumour of the ovary{"}) OR {"}ovarian tumor{"}) OR {"}ovarian tumors{"}) OR {"}ovarian tumour{"}) OR {"}ovarian tumours{"}) OR {"}ovarian neoplasm{"}) OR {"}ovarian neoplasms{"} OR {"}ovarian carcinoma{"}) OR {"}ovarian carcinomas{"}) OR {"}carcinoma of the ovary{"})) AND ((((((((({"}epigenetics{"}) OR {"}epigenetic{"}) OR {"}epigenome{"}) OR {"}methylation{"}) OR {"}hypermethylation{"}) OR {"}chromatin modification{"}) OR {"}histone{"}) OR {"}histones{"}) OR {"}acetylation{"}) Expert opinion: To date no single epigenetic biomarker is able to accurately detect early ovarian cancer in either tissue or body fluids. A panel of epigenetic biomarkers based on aberrant DNA methylation in body fluids, especially blood, has the best chance of being implemented in clinical practice, as it is semi-invasive. However, progression toward clinical use is hampered by the lack of detection techniques combining high throughput and accuracy with low cost, by difficulties in establishing reliable reference values and by the heterogeneous nature of ovarian cancer. Until addressed, implementation as a diagnostic measure complimenting current techniques in select cases seems a far way to go, and implementation as a primary screening tool is yet even farther away.",
keywords = "biomarkers, borderline tumor, chromatin modification, diagnosis, epigenetics, methylation, ovarian cancer",
author = "Bijron, {Jonathan G.} and Bol, {Guus M.} and Verheijen, {Rene H M} and {Van Diest}, {Paul J.}",
year = "2012",
month = "9",
doi = "10.1517/17530059.2012.702105",
language = "English (US)",
volume = "6",
pages = "421--438",
journal = "Expert Opinion on Medical Diagnostics",
issn = "1753-0059",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Epigenetic biomarkers in the diagnosis of ovarian cancer

AU - Bijron, Jonathan G.

AU - Bol, Guus M.

AU - Verheijen, Rene H M

AU - Van Diest, Paul J.

PY - 2012/9

Y1 - 2012/9

N2 - Current diagnostic methods for ovarian cancer have limited performance. Recent advances within the field of epigenetics have shifted the clinical implementation of epigenetic biomarkers as a diagnostic approach from a dream for the future to a present-day consideration. Patients could potentially benefit greatly from this novel diagnostic approach. Areas covered: Epigenetic mechanisms in cancer are discussed, with a focus on potential diagnostic epigenetic biomarkers in ovarian cancer in tissue and body fluids. A literature search was undertaken (on 22-09-2011) for these subjects using the search syntax ((((((((((((((("ovarian") OR "ovary") OR "ovarian cancer") OR "ovarian cancers") OR "cancer of the ovary") OR "tumour of the ovary") OR "ovarian tumor") OR "ovarian tumors") OR "ovarian tumour") OR "ovarian tumours") OR "ovarian neoplasm") OR "ovarian neoplasms" OR "ovarian carcinoma") OR "ovarian carcinomas") OR "carcinoma of the ovary")) AND ((((((((("epigenetics") OR "epigenetic") OR "epigenome") OR "methylation") OR "hypermethylation") OR "chromatin modification") OR "histone") OR "histones") OR "acetylation") Expert opinion: To date no single epigenetic biomarker is able to accurately detect early ovarian cancer in either tissue or body fluids. A panel of epigenetic biomarkers based on aberrant DNA methylation in body fluids, especially blood, has the best chance of being implemented in clinical practice, as it is semi-invasive. However, progression toward clinical use is hampered by the lack of detection techniques combining high throughput and accuracy with low cost, by difficulties in establishing reliable reference values and by the heterogeneous nature of ovarian cancer. Until addressed, implementation as a diagnostic measure complimenting current techniques in select cases seems a far way to go, and implementation as a primary screening tool is yet even farther away.

AB - Current diagnostic methods for ovarian cancer have limited performance. Recent advances within the field of epigenetics have shifted the clinical implementation of epigenetic biomarkers as a diagnostic approach from a dream for the future to a present-day consideration. Patients could potentially benefit greatly from this novel diagnostic approach. Areas covered: Epigenetic mechanisms in cancer are discussed, with a focus on potential diagnostic epigenetic biomarkers in ovarian cancer in tissue and body fluids. A literature search was undertaken (on 22-09-2011) for these subjects using the search syntax ((((((((((((((("ovarian") OR "ovary") OR "ovarian cancer") OR "ovarian cancers") OR "cancer of the ovary") OR "tumour of the ovary") OR "ovarian tumor") OR "ovarian tumors") OR "ovarian tumour") OR "ovarian tumours") OR "ovarian neoplasm") OR "ovarian neoplasms" OR "ovarian carcinoma") OR "ovarian carcinomas") OR "carcinoma of the ovary")) AND ((((((((("epigenetics") OR "epigenetic") OR "epigenome") OR "methylation") OR "hypermethylation") OR "chromatin modification") OR "histone") OR "histones") OR "acetylation") Expert opinion: To date no single epigenetic biomarker is able to accurately detect early ovarian cancer in either tissue or body fluids. A panel of epigenetic biomarkers based on aberrant DNA methylation in body fluids, especially blood, has the best chance of being implemented in clinical practice, as it is semi-invasive. However, progression toward clinical use is hampered by the lack of detection techniques combining high throughput and accuracy with low cost, by difficulties in establishing reliable reference values and by the heterogeneous nature of ovarian cancer. Until addressed, implementation as a diagnostic measure complimenting current techniques in select cases seems a far way to go, and implementation as a primary screening tool is yet even farther away.

KW - biomarkers

KW - borderline tumor

KW - chromatin modification

KW - diagnosis

KW - epigenetics

KW - methylation

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84865515837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865515837&partnerID=8YFLogxK

U2 - 10.1517/17530059.2012.702105

DO - 10.1517/17530059.2012.702105

M3 - Article

C2 - 23480807

AN - SCOPUS:84865515837

VL - 6

SP - 421

EP - 438

JO - Expert Opinion on Medical Diagnostics

JF - Expert Opinion on Medical Diagnostics

SN - 1753-0059

IS - 5

ER -